Glyrax M1 is used in the treatment of type 2 diabetes. This is a combination of two antidiabetic medicines: Glimepride and Metformin. Glimepiride stimulates the insulin release from functioning pancreatic ?-cells and inhibits gluconeogenesis at hepatic cells. It also increases insulin sensitivity at peripheral target sites. Metformin decreases hepatic gluconeogenesis, decreases intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilisation).